中国卵巢高级别浆液性癌的多中心队列:叶酸受体α表达异质性与分子标志物关联
该回顾性多中心研究纳入中国14家医院1002例切除的卵巢高级别浆液性癌(HGSC)患者,采用VENTANA FOLR1(FOLR1-2.1)RxDx检测评估叶酸受体α(FRα)表达。结果显示43.41%(435/1002)肿瘤为高表达(≥75%活肿瘤细胞2+/3+膜染色),且瘤内染色强度混合常见(93.1%同时含阴性/弱与中/强细胞群);与临床病理特征及BRCA1/2、HRD等标志物无显著关联(检验受限)。53对原发与复发肿瘤分类一致率71.7%(κ=0.44),FRα百分比中度相关(ρ=0.59)。
要点
- 中国HGSC队列中43.41%为FRα高表达(≥75%细胞2+/3+),但瘤内强度混合普遍。
- FRα表达与年龄、FIGO分期、肿瘤大小及所测分子标志物无显著关联,检验效能有限。
- 原发与复发肿瘤FRα分类一致率71.7%(κ=0.44),支持存档检测,不一致者可考虑复发时复测。
核心结论
- FRα在卵巢HGSC中表达异质性显著,瘤内常见强度混合,高表达占43.41%。
- FRα与所评估的临床病理特征及分子标志物无显著关联,但相关分析受限且检验效能不足。
- 原发与复发肿瘤FRα表达中度一致,支持存档样本检测,不一致时部分患者可考虑复发时复测。
研究设计与样本
- 回顾性多中心队列研究,纳入中国14家医院1002例切除的卵巢高级别浆液性癌(HGSC)患者。
- 采用VENTANA FOLR1(FOLR1-2.1)RxDx检测评估FRα膜染色,高表达定义为≥75%活肿瘤细胞呈2+/3+染色。
- 992例有染色强度分类数据;53对原发与复发肿瘤用于评估时间一致性。
主要发现
- 1002例中435例(43.41%)为FRα高表达(≥75%活肿瘤细胞2+/3+膜染色)。
- 992例有强度数据者中,972例(98.0%)含至少两种染色类别,924例(93.1%)同时含阴性或弱与中或强肿瘤细胞群。
- 与年龄、FIGO分期、肿瘤大小及BRCA1/2、HRD、TMB、MSI、MMR、HER2、PD-L1无显著关联(分析受限、效能不足)。
- 53对原发与复发肿瘤分类一致率71.7%(Cohen's κ=0.44),FRα百分比中度相关(Spearman ρ=0.59)。
关键数值与推荐
- FRα高表达判定标准:≥75%活肿瘤细胞呈2+/3+膜染色。
- 瘤内异质性:992例中98.0%含至少两种染色类别,93.1%同时含阴性/弱与中/强细胞群。
- 原发-复发一致性:分类一致率71.7%,κ=0.44;FRα百分比Spearman ρ=0.59。
临床怎么用
- 对HGSC患者可基于手术标本行FRα免疫组化检测以筛选潜在FRα靶向治疗候选者。
- 因瘤内染色强度混合常见,判读时应关注≥75%活肿瘤细胞2+/3+的阈值定义。
- 原发与复发表达中度一致,存档样本检测可作参考,复发时不一致者可在部分患者中复测。
局限性
- 为回顾性研究设计。
- 与临床病理特征及分子标志物的关联分析检验受限且效能不足,结论不确定。
- 原发与复发一致性分析仅基于53对肿瘤,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Folate receptor alpha (FRα) is an established therapeutic target in ovarian cancer, but information on its expression distribution, staining heterogeneity, and molecular context in Chinese patients remains limited. We evaluated these features in ovarian high grade serous carcinoma (HGSC). METHODS: This retrospective multicenter study included 1002 patients with resected HGSC from 14 Chinese hospitals. FRα expression was assessed using the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay based on the percentage of viable tumor cells with moderate or strong (2+/3+) membranous staining. Intensity specific percentages were available for 992 tumors. Associations with clinicopathologic features and BRCA1/2, HRD, TMB, MSI, MMR, HER2, and PD-L1 were exploratory. Temporal concordance was evaluated in 53 paired primary and recurrent tumors. RESULTS: High FRα expression, defined as 2+/3+ staining in ≥75% of viable tumor cells, was observed in 435 of 1002 tumors (43.41%). Among 992 tumors with intensity data, 972 (98.0%) contained at least two staining categories, and 924 (93.1%) contained both negative or weak and moderate or strong tumor cell populations. No significant associations were detected with age, FIGO stage, tumor size, or the biomarkers evaluated, although analyses were limited and underpowered. Paired tumors showed 71.7% categorical agreement (Cohen's κ = 0.44) and moderate correlation of FRα percentages (Spearman ρ = 0.59). CONCLUSIONS: FRα expression showed substantial variation between tumors and frequent intensity admixture within specimens. Biomarker associations remain inconclusive because of limited testing. Moderate primary and recurrent concordance supports archival testing, while discordance suggests repeat testing at recurrence may be appropriate in selected patients.
引用
- Li F, Li D, Xi Y, et al. Heterogeneity of folate receptor alpha expression and associations with molecular biomarker in ovarian high-grade serous carcinoma: A multicenter Chinese cohort study. Gynecol Oncol. 2026. PMID: 42945832. doi:10.1016/j.ygyno.2026.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。